Amgen reports 58 percent lower death risk in trial for Amgen stock

Amgen stock was at EUR 395.63 at Lang & Schwarz on October 26, 2026, as the company presented Phase 3 data showing a 58.00 percent lower risk of death for an Imdelltra and Imfinzi combination. The announcement dated October 24, 2026, gives Amgen's oncology pipeline a fresh clinical reference point, but regulatory review and commercial execution remain the next tests.

Trial results sharpen the oncology case

According to Amgen on October 24, 2026, the DeLLphi-305 study found median overall survival of 21.10 months with the combination, versus 12.70 months with Imfinzi alone. Progression-free survival was 7.40 months versus 1.90 months, while 20.90 percent of patients in the combination group had Grade 3 or higher treatment-related adverse events, compared with 10.80 percent for Imfinzi alone.

The result was also reported by Reuters on October 24, 2026. The 563-patient trial tested first-line maintenance treatment in extensive-stage small cell lung cancer, and nearly 80.00 percent of combination patients were alive after one year versus 53.00 percent with Imfinzi alone.

Three dates frame Amgen's pipeline

Amgen's recent sequence has three measurable steps: on August 4, 2026, second-quarter revenue reached USD 10.05 billion and adjusted earnings per share reached USD 6.29; on October 20, 2026, the company highlighted Tezspire data in eosinophilic esophagitis; and on October 24, 2026, the Imdelltra combination produced the 58.00 percent reduction in death risk. The company also raised its 2026 revenue outlook to USD 38.2 billion-USD 39.4 billion after the second quarter, according to its investor materials.

What does the data mean for growth?

The answer depends on whether the trial result moves Imdelltra into earlier treatment. Amgen's second-quarter oncology portfolio generated about USD 2.0 billion, while Imdelltra sales rose 115.00 percent year over year to USD 288.0 million. That contrast shows both the opportunity and the scale still required before the new indication can materially reshape the company.

Stock context and investor view

Amgen's primary listing is on Nasdaq under AMGN, and its market capitalization was USD 237.5 billion as of October 23, 2026. The same quote showed a USD 288.00 to USD 450.98 52-week range. The clinical evidence adds a concrete pipeline variable ahead of the company's next reported results, while the adverse-event figures provide a counterweight to the efficacy signal.

Clinical evidence meets market value

The combination's 21.10-month median survival result gives investors a clear measure for judging future regulatory and commercial progress.

Amgen stock was trading at EUR 395.63 at Lang & Schwarz on October 26, 2026, at 11:03 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.

Market context: Market report S&P 500.

More news and analyses on Amgen stock